Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis

Liver International

Volumn 25, Issue 2, 2005, Pages 311-316

  Campbell, Mical S ^a   Lichtenstein, Gary R ^a   Rhim, Andrew D ^a   Pazianas, Michael ^a   Faust, Thomas ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bone density; Bone diseases; Cholangitis; Densitometry; Metabolic; Osteoporosis; Sclerosing; X ray

Indexed keywords

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; LUMBAR SPINE; MALE; METABOLIC BONE DISEASE; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PREDICTION; PRIMARY SCLEROSING CHOLANGITIS; RISK FACTOR; SCORING SYSTEM;

ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; BONE DENSITY; BONE DISEASES, METABOLIC; CHOLANGITIS, SCLEROSING; DENSITOMETRY, X-RAY; FEMALE; HUMANS; INCIDENCE; LINEAR MODELS; LIVER DISEASES; MALE; MIDDLE AGED; OSTEOPOROSIS; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 17044407569     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01075.x     Document Type: Article

References (15)

1. Lindor K D, Janes C H, Crippin J S, et al. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995; 21: 389-92.
2. Eastell R, Dickson E R, Hodgson S F, et al. Rate of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14: 296-300.
3. Menon K V, Angulo P, Weston S, et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001; 35: 316-23.
4. Newton J, Francis R, Prince M, et al. Osteoporosis in PBC revisited. Gut 2001; 49: 282-7.
5. Le Gars L, Grandpierre C, Chazouilleres O, et al. Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease. Joint, Bone, Spine: Revue du Rhumatisme 2002; 69: 195-200.
6. Hay J E, Lindor K D, Wiesner R H, et al. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991; 14: 257-61.
7. Angulo P, Therneau T M, Jorgensen R A, et al. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity, and prediction of progression. J Hepatol 1998; 29: 729-35.
8. Kamath P S, Weisner R H, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
9. Kim W R, Therneau T M, Wiesner R H, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75: 688-94.
10. Anonymus. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-50.
11. Genant H K, Grampp S, Gluer C C, et al. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 1994; 9: 1503-14.
12. Guichelaar M M, Malinchoc M, Sibonga J, et al. Bone metabolism in advanced cholestatic liver disease: analysis by bone histomorphometry. Hepatology 2002; 36: 895-903.
13. Stellon A J, Webb A, Compston J, et al. Lack of osteomalacia in chronic cholestatic liver disease. Bone 1986; 7: 181-5.
14. Janes C H, Dickson E R, Okazaki R, et al. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995; 95: 2581-6.
15. Arnold J C, Hauser D, Ziegler R, et al. Bone disease after liver transplantation. Transplant Proc 1992; 24: 2709-10.